• Citer

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.

par Ignatiadis, M;Litière, Saskia;Rothe, F;Riethdorf, Sabine;Proudhon, Charlotte;Fehm, T;Aalders, Kim K.C.;Forstbauer, Helmut;Fasching, P A;Brain, E;Vuylsteke, P;Guardiola, E;Lorenz, R;Pantel, K;Tryfonidis, Konstantinos;Janni, Wolfgang;Piccart, M;Sotiriou, Christos ;Rack, B;Pierga, J-Y
Référence Annals of oncology, 29, 8, page (1777-1783)
Publication Publié, 2018-03-01

Article révisé par les pairs

• Détails
• Contenu

Titre:	Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
Auteur:	Ignatiadis, M; Litière, Saskia; Rothe, F; Riethdorf, Sabine; Proudhon, Charlotte; Fehm, T; Aalders, Kim K.C.; Forstbauer, Helmut; Fasching, P A; Brain, E; Vuylsteke, P; Guardiola, E; Lorenz, R; Pantel, K; Tryfonidis, Konstantinos; Janni, Wolfgang; Piccart, M; Sotiriou, Christos; Rack, B; Pierga, J-Y
Informations sur la publication:	Annals of oncology, 29, 8, page (1777-1783)
Statut de publication:	Publié, 2018-03-01
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Antineoplastic Agents, Immunological -- administration & dosage -- adverse effects
	Breast -- pathology -- surgery
	Breast Neoplasms -- blood -- mortality -- therapy
	Cardiotoxicity -- epidemiology -- etiology
	Chemotherapy, Adjuvant -- methods
	Disease-Free Survival
	Female
	Humans
	Mastectomy
	Middle Aged
	Neoplastic Cells, Circulating -- drug effects
	Receptor, ErbB-2 -- antagonists & inhibitors -- metabolism
	Trastuzumab -- administration & dosage -- adverse effects
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdy211
	info:pii/S0923-7534(19)34129-8
	info:pmid/29893791